Uncommon Cents Investing LLC Acquires 3,715 Shares of Bristol-Myers Squibb (NYSE:BMY)

Uncommon Cents Investing LLC grew its holdings in Bristol-Myers Squibb (NYSE:BMY) by 69.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 9,045 shares of the biopharmaceutical company’s stock after purchasing an additional 3,715 shares during the period. Uncommon Cents Investing LLC’s holdings in Bristol-Myers Squibb were worth $464,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Austin Private Wealth LLC lifted its holdings in Bristol-Myers Squibb by 27.2% during the 4th quarter. Austin Private Wealth LLC now owns 4,643 shares of the biopharmaceutical company’s stock worth $238,000 after buying an additional 994 shares during the period. Ritholtz Wealth Management increased its holdings in Bristol-Myers Squibb by 4.8% during the 4th quarter. Ritholtz Wealth Management now owns 15,665 shares of the biopharmaceutical company’s stock worth $804,000 after purchasing an additional 720 shares in the last quarter. Accel Wealth Management increased its holdings in Bristol-Myers Squibb by 12.7% during the 4th quarter. Accel Wealth Management now owns 4,146 shares of the biopharmaceutical company’s stock worth $213,000 after purchasing an additional 467 shares in the last quarter. WASHINGTON TRUST Co increased its holdings in Bristol-Myers Squibb by 6.1% during the 4th quarter. WASHINGTON TRUST Co now owns 15,460 shares of the biopharmaceutical company’s stock worth $793,000 after purchasing an additional 894 shares in the last quarter. Finally, Next Level Private LLC grew its holdings in shares of Bristol-Myers Squibb by 8.2% in the fourth quarter. Next Level Private LLC now owns 58,223 shares of the biopharmaceutical company’s stock valued at $2,987,000 after acquiring an additional 4,412 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on BMY shares. Wells Fargo & Company reduced their target price on Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating for the company in a report on Tuesday, February 6th. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Bank of America downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Finally, Redburn Atlantic downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $61.12.

Bristol-Myers Squibb Price Performance

BMY traded up $0.98 during trading on Thursday, reaching $54.23. The stock had a trading volume of 14,346,012 shares, compared to its average volume of 16,860,898. The stock has a market cap of $109.91 billion, a PE ratio of 14.08, a PEG ratio of 1.59 and a beta of 0.38. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43. Bristol-Myers Squibb has a one year low of $47.58 and a one year high of $71.07. The business has a 50-day moving average of $50.79 and a 200-day moving average of $52.44.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. The business had revenue of $11.48 billion for the quarter, compared to analysts’ expectations of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The firm’s revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.82 earnings per share. As a group, equities research analysts anticipate that Bristol-Myers Squibb will post 6.61 EPS for the current fiscal year.

Bristol-Myers Squibb declared that its Board of Directors has initiated a share buyback plan on Thursday, December 7th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to repurchase up to 2.9% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s management believes its shares are undervalued.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a $0.60 dividend. The ex-dividend date is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.43%. Bristol-Myers Squibb’s dividend payout ratio is presently 62.18%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.